Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients - Concepedia

Concepedia

Publication | Closed Access

Phase II Study of G3139, a Bcl-2 Antisense Oligonucleotide, in Combination With Dexamethasone and Thalidomide in Relapsed Multiple Myeloma Patients

96

Citations

35

References

2005

Year

Ashraf Badros, Olga Goloubeva, Aaron P. Rapoport, Bashi Ratterree, Natalie Gahres, Barry Meisenberg, Naoko Takebe, Meyer R. Heyman, James A. Zwiebel, Howard Streicher,

Journal of Clinical Oncology

Abstract

G3139, dexamethasone, and thalidomide are well tolerated and result in encouraging clinical responses in relapsed multiple myeloma patients.

References

	Year	Citations

Page 1